So to give some context, chondrosarcomas are rare tumors of bone arising from the cartilage. They’re the second most common primary bone tumor. And in about 40 to 65% of cases, these tumors are characterized by mutations in either IDH1 and IDH2. Treatment options for patients with advanced or metastatic chondrosarcoma are limited. There are no effective systemic therapies...
So to give some context, chondrosarcomas are rare tumors of bone arising from the cartilage. They’re the second most common primary bone tumor. And in about 40 to 65% of cases, these tumors are characterized by mutations in either IDH1 and IDH2. Treatment options for patients with advanced or metastatic chondrosarcoma are limited. There are no effective systemic therapies. Therefore, targeting IDH1 in advanced and metastatic chondrosarcoma is a very attractive option. There are promising phase one data from two trials of IDH1 inhibitors in advanced or metastatic chondrosarcoma and these data support the rationale for the ongoing phase three trial of ivosidenib versus placebo in patients with advanced chondrosarcoma and that trial is currently recruiting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
